75 results on '"Gainor, J."'
Search Results
2. Susan Glaspell (1876–1948)
3. The Routledge Anthology of Women's Theatre Theory and Dramatic Criticism
4. Jacques Copeau's “The Spirit in the Little Theatre”: Contexts and Texts
5. 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy
6. 1O Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial)
7. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
8. 1170P Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)
9. 984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)
10. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
11. Quantitative Evaluation of Normal Lung Density Changes in Non-Small Cell Lung Cancer Patients Treated With Radiotherapy and PD-1 Immune Checkpoint Inhibitors
12. Fabian drama
13. SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
14. Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)
15. OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
16. P75.03 KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC
17. P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status
18. OA05.02 Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study
19. Activité intracrânienne du selpercatinib (LOXO-292) chez les patients atteints d’un cancer bronchique non à petites cellules (CBNPC) exprimant le gène de fusion RET dans le cadre de l’essai LIBRETTO-001
20. Dance Nationand Its Representational Challenges
21. Susan Glaspell and Sophie Treadwell: Staging Feminism and Modernism, 1915-1941
22. Albee’s The Goat
23. Screening of ‘unbiased’ immobilized peptide library vs. proteases: An approach for rapid determination of substrate specificity and selectivity
24. Immobilized peptide arrays: A new technology for the characterization of protease function
25. Relationship between structure and bio-availability in a series of hydroxamate based metalloprotease inhibitors
26. The synthesis and coupling efficiency of 7-hydroxycoumarin-4-propionic acid, a fluorescent marker useful in immobilized substrate libraries
27. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
28. MS01.01 Biological Mechanisms of Resistance
29. MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%
30. MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement
31. MA16.08 Clinical Utility of Detecting ROS1 Genetic Alterations in Plasma
32. P1.04-21 The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
33. P2.04-23 Immune-Related Adverse Events: The Growing Pains of Immunooncology
34. MA08.05 Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study
35. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
36. Granville Barker on Theatre: Selected Essays by Harley Granville Barker
37. P3.07-012 Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases
38. MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC
39. P1.07-033 Differential Expression of Immune Inhibitory Markers in Association with the Immune Microenvironment in Resected Lung Adenocarcinomas
40. OA 07.05 Serial Biopsies in Patients with EGFR-Mutant NSCLC Highlight the Spatial and Temporal Heterogeneity of Resistance Mechanisms
41. OA 12.02 Final Results of a Phase 2 Study of the hsp90 Inhibitor Luminespib (AUY922) in NSCLC Patients Harboring EGFR Exon 20 Insertions
42. MA 07.07 Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant
43. Local Control and Distant Brain Failure in Patients Treated With Concurrent Radiation and PD-1/PDL-1 Inhibitors
44. CNS Radiation-Related Adverse Events in Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors
45. Incidence of Pneumonitis in Metastatic Lung Cancer Patients Receiving Immune Checkpoint Inhibitors With or Without Thoracic Radiation Therapy
46. Robust Correlation between Immediate Post Radio-Chemotherapy FDG PET Response and Clinical Outcome and Impact of Salvage Radiation for Partial Metabolic Responders in Locally Advanced Non–Small Cell Lung Cancer
47. Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy
48. 481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy
49. 481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy
50. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.